Bio Cell Products Achieving Higher Viability via Laminar Flow

In the final stages of biopharmaceutical production, bioactivity stands as the ultimate measure of process success. For cell therapies, antibody drugs, and vaccine manufacturing, even minimal shear damage during product transfer can degrade product quality or cause expensive batch failures. That’s where our Disc Pump technology makes a decisive difference — ensuring stability and high recovery of expensive biological media through its signature laminar flow process.

1. Live Cell Products: Maintaining Exceptional Viability and Metabolic Activity

When producing stem cells or immune cells, the integrity of finished cells is non-negotiable. Our Disc Pump mimics natural fluid states, creating a laminar environment that avoids the tearing of cell membranes caused by mechanical blades. The result: cell products retain their original morphology and organelle integrity. Empirical data consistently show that cell viability after Disc Pump transfer is significantly higher than with conventional systems. This means your finished products possess stronger proliferation capacity and metabolic activity, directly enhancing clinical efficacy and patient outcomes.

2. Protein and Antibody Products: Ensuring Structural Integrity and Zero Aggregation

For high-value monoclonal antibodies (mAbs) or recombinant proteins, product purity depends entirely on molecular structure protection. Our ultra-low shear stress prevents denaturation of long protein chains, so your finished products exhibit exceptional stability with intact secondary and tertiary structures. Additionally, the process effectively suppresses abnormal molecular aggregation — ensuring your finished liquid products remain clear, sediment-free, and compliant with the most stringent pharmacopeia standards. No more costly reprocessing or batch rejections due to aggregation issues.

3. Blood and Vaccine Products: Preventing Hemolysis and Maintaining Antigen Activity

In blood product fractionation and packaging, our Disc Pump achieves truly “wearless” transfer, completely eliminating hemolysis caused by red blood cell rupture. For vaccine manufacturing, the laminar flow process protects sensitive antigen structures from physical impact, preserving immunogenicity and long-term stability. Every batch comes out with zero hemolysis guarantee and full antigen potency — a game-changer for regulatory compliance and patient safety.

The Disc Pump is your ultimate barrier for finished product quality. By reducing process loss and enhancing bioactivity, it ensures every batch achieves the highest levels of compliance and therapeutic stability. Invest in laminar flow technology today — and turn your production challenges into competitive advantage. When your end-product viability matters, choose the pump that delivers consistency, purity, and profitability.